FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
Identification of serum biomarkers associated with Aramchol treatment.... | Download Scientific Diagram
Diabetes & Metabolism Journal
One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial | Nature Medicine
Aramchol - Wikipedia
Aramchol attenuated lipid accumulation and ROS production in... | Download Scientific Diagram
Frontiers | Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments | Pharmacology
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease - Clinical Gastroenterology and Hepatology
Frontiers | Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments | Pharmacology
Galmed: A Deep-Dive Analysis Of The ARREST Trial (NASDAQ:GLMD) | Seeking Alpha
Aramchol™ reduces fibrosis progression in 24 weeks
Drug discovery and treatment paradigms in nonalcoholic steatohepatitis - Noureddin - 2020 - Endocrinology, Diabetes & Metabolism - Wiley Online Library
Therapeutic pipeline in nonalcoholic steatohepatitis | Nature Reviews Gastroenterology & Hepatology
Key targets for drugs in phase 2 and phase 3 clinical trials. | Download Scientific Diagram
One-year results of the Global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH patients
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
New Data on Aramchol TM for the Treatment of Non-alcoholic Steatohepatitis: Exploring Potential for Greater Efficacy and the Effect on Glucose Metabolism - European Medical Journal
The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease - Clinical Gastroenterology and Hepatology
EX-99.1 2 tm216865d1_ex99-1.htm EXHIBIT 99.1 Exhibit
Galmed closes patient enrolment for Phase IIb ARREST study of Aramchol to treat liver diseases - Clinical Trials Arena
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
